Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios

Am J Obstet Gynecol. 2009 Jul;201(1):e13-4. doi: 10.1016/j.ajog.2009.02.017. Epub 2009 Apr 26.

Abstract

Herceptin (trastuzumab) is an adjuvant chemotherapy agent used in treatment of certain breast cancers. Limited information is available on the use of herceptin in pregnancy. This case is a twin pregnancy exposed to herceptin until 23 weeks' gestation. One twin had chronic renal failure develop, whereas the other twin did not.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amniotic Fluid / drug effects
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Carcinoma, Ductal, Breast / drug therapy
  • Chemotherapy, Adjuvant
  • Creatinine / blood
  • Diseases in Twins / chemically induced
  • Fatal Outcome
  • Female
  • Humans
  • Infant, Newborn
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / chemically induced
  • Oligohydramnios / epidemiology*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Pregnancy Outcome*
  • Pregnancy, Multiple*
  • Prenatal Exposure Delayed Effects / chemically induced
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Creatinine
  • Trastuzumab